AVALO THERAPEUTICS, INC. Depreciation
AVALO THERAPEUTICS, INC. (AVTX) reported Depreciation of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. depreciation for the quarter ending 2017-12-31 was $4.91K, a 23.20% decline year-over-year.
- AVALO THERAPEUTICS, INC. depreciation for the quarter ending 2017-09-30 was $5.36K, a 23.98% decline year-over-year.
- AVALO THERAPEUTICS, INC. depreciation for the quarter ending 2017-06-30 was $5.86K, a 11.60% decline year-over-year.
- AVALO THERAPEUTICS, INC. depreciation for the quarter ending 2017-03-31 was $5.83K, a 14.11% decline year-over-year.
- AVALO THERAPEUTICS, INC. depreciation for fiscal 2025 was $300.00K, a 50.00% increase from fiscal 2024.
- AVALO THERAPEUTICS, INC. depreciation for fiscal 2024 was $200.00K, a 0.00% change from fiscal 2023.
- AVALO THERAPEUTICS, INC. depreciation for fiscal 2023 was $200.00K, a 100.00% increase from fiscal 2022.
- AVALO THERAPEUTICS, INC. depreciation for fiscal 2022 was $100.00K, a 0.00% change from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $200.00K 10-K · filed 2026-03-23 | ||||
| 2023-12-31 | $200.00K 10-K · filed 2025-03-20 | ||||
| 2022-12-31 | $100.00K 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | $100.00K 10-K · filed 2023-03-29 | ||||
| 2020-12-31 | $100.00K 10-K · filed 2022-03-02 | $102.09K 10-K · filed 2021-03-08 | |||
| 2019-12-31 | $119.49K 10-K · filed 2021-03-08 | ||||
| 2018-12-31 | $22.52K 10-K · filed 2020-03-11 | ||||
| 2017-12-31 | $4.91K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $10.27K derived: sum of 2 quarters · filed 2019-03-18 | $16.13K derived: sum of 3 quarters · filed 2019-03-18 | $21.96K 10-K · filed 2019-03-18 | |
| 2017-09-30 | $5.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $11.22K derived: sum of 2 quarters · filed 2017-11-07 | $17.05K 10-Q · filed 2017-11-07 | $23.44K derived: sum of 4 quarters · filed 2018-04-02 | |
| 2017-06-30 | $5.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $11.69K 10-Q · filed 2017-08-14 | $18.08K derived: sum of 3 quarters · filed 2018-04-02 | $25.13K derived: sum of 4 quarters · filed 2018-04-02 | |
| 2017-03-31 | $5.83K 10-Q · filed 2017-05-09 | $12.22K derived: sum of 2 quarters · filed 2018-04-02 | $19.27K derived: sum of 3 quarters · filed 2018-04-02 | $25.90K derived: sum of 4 quarters · filed 2018-04-02 | |
| 2016-12-31 | $6.39K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $13.44K derived: sum of 2 quarters · filed 2018-04-02 | $20.07K derived: sum of 3 quarters · filed 2018-04-02 | $26.86K 10-K · filed 2018-04-02 | |
| 2016-09-30 | $7.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $13.68K derived: sum of 2 quarters · filed 2017-11-07 | $20.47K 10-Q · filed 2017-11-07 | $26.62K derived: sum of 4 quarters · filed 2017-11-07 | |
| 2016-06-30 | $6.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $13.42K 10-Q · filed 2017-08-14 | $19.56K derived: sum of 3 quarters · filed 2017-08-14 | $25.89K derived: sum of 4 quarters · filed 2017-08-14 | |
| 2016-03-31 | $6.79K 10-Q · filed 2017-05-09 | $12.94K derived: sum of 2 quarters · filed 2017-05-09 | $19.26K derived: sum of 3 quarters · filed 2017-05-09 | $24.78K derived: sum of 4 quarters · filed 2017-05-09 | |
| 2015-12-31 | $6.15K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $12.47K derived: sum of 2 quarters · filed 2017-03-14 | $17.99K derived: sum of 3 quarters · filed 2017-03-14 | $23.51K 10-K · filed 2017-03-14 | |
| 2015-09-30 | $6.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $11.84K derived: sum of 2 quarters · filed 2016-11-08 | $17.36K 10-Q · filed 2016-11-08 | $25.24K derived: sum of 4 quarters · filed 2017-03-14 | |
| 2015-06-30 | $5.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $11.04K 10-Q · filed 2016-08-15 | $18.92K derived: sum of 3 quarters · filed 2017-03-14 | ||
| 2015-03-31 | $5.52K 10-Q · filed 2016-05-16 | $13.40K derived: sum of 2 quarters · filed 2017-03-14 | |||
| 2014-12-31 | $7.88K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $28.94K 10-K · filed 2017-03-14 | |||
| 2014-09-30 | $21.06K 10-Q · filed 2015-11-13 | ||||
| 2013-12-31 | $20.03K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |